Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Rises By 252.8%

Pulmatrix, Inc. (NASDAQ:PULM) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 12,700 shares, an increase of 252.8% from the September 15th total of 3,600 shares. Based on an average trading volume of 12,700 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.4% of the company’s shares are sold short. Currently, 0.4% of the company’s shares are sold short. Based on an average trading volume of 12,700 shares, the days-to-cover ratio is presently 1.0 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pulmatrix stock. SBI Securities Co. Ltd. increased its position in Pulmatrix, Inc. (NASDAQ:PULM) by 15.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 60,565 shares of the biotechnology company’s stock after purchasing an additional 8,208 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Pulmatrix were worth $418,000 as of its most recent filing with the Securities & Exchange Commission. 11.84% of the stock is currently owned by institutional investors.

Pulmatrix Trading Up 5.2%

NASDAQ PULM opened at $4.88 on Friday. Pulmatrix has a fifty-two week low of $1.96 and a fifty-two week high of $10.40. The stock has a 50 day simple moving average of $4.82 and a two-hundred day simple moving average of $5.98.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Thursday, October 16th. The biotechnology company reported ($0.24) earnings per share for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.